Table 3.
Adverse Events.
| Characteristic | Atezolizumab plus cabozantinib (N=262) | Cabozantinib (N=256) |
|---|---|---|
| Any-cause adverse event | 262 (100%) | 254 (99%) |
| Any-cause adverse event related to treatment | 252 (96%) | 249 (97%) |
| Grade 3 or 4 event | 177 (68%) | 158 (62%) |
| Grade 3 or 4 event related to treatment | 145 (55%) | 121 (47%) |
| Death due to adverse event | 17 (6%) | 9 (4%) |
| Death due to adverse event related to treatment | 3 (1%) | 0 |
| Serious adverse event | 126 (48%) | 84 (33%) |
| Serious adverse event related to treatment | 63 (24%) | 30 (12%) |
| Adverse event leading to withdrawal from a trial drug | 41 (16%) | 10 (4%) |
| Adverse event leading to withdrawal from atezolizumab | 29 (11%) | 0 |
| Adverse event leading to withdrawal from cabozantinib | 25 (10%) | 10 (4%) |
| Adverse event leading to interruption or reduction of a trial drug | 240 (92%) | 223 (87%) |
| Adverse event leading to interruption of atezolizumab | 159 (61%) | 0 |
| Adverse event leading to interruption or reduction of cabozantinib | 234 (89%)* | 223 (87%)† |
Data are n (%).
*
Due to an adverse event, 103 (39%) patients had dose reductions to a lowest dose of cabozantinib 40 mg, and 98 (37%) had a lowest dose of 20 mg
†
Due to an adverse event, 104 (41%) patients had dose reductions to a lowest dose of cabozantinib 40 mg, and 77 (30%) had a lowest dose of 20 mg.